Description of the medicine: Ceruloplasmin (Ceruloplasminum)
Glycoprotein a-globulin fraction of human serum.
Available for medical use in the form of a lyophilized amorphous powder or porous mass of blue color (Blue color is due to the content of copper ions in the glycoprotein.). Soluble in water, forms a slightly opaque solution of blue color. Hygroscopic.
Ceruloplasmin is a plasma protein that performs a number of important biological functions in the body; increases the stability of cell membranes, participates in immunological reactions, ion exchange, has an antioxidant effect, inhibits lipid peroxidation, stimulates hematopoiesis. The content of ceruloplasmin in serum is significantly reduced during hepatocerebral degeneration (Wilson-Konovalov disease), which is an important diagnostic indicator.
As a medicine, it is used to stimulate hematopoiesis, reduce intoxication and immunological correction in the complex therapy of cancer patients; during preoperative preparation in debilitated patients with anemia, exhaustion, intoxication; in the early postoperative period in case of massive blood loss during surgery; with purulent-septic complications in early postoperative chemotherapy of cancer patients, including patients with hemoblastoses with mild intoxication.
Ceruloplasmin is also used in the treatment of patients with acute and chronic osteomyelitis.
Enter intravenously (30 drops per minute). The contents of 1 vial or ampoule are dissolved in 200 ml of 5% glucose solution or isotonic sodium chloride solution.
To cancer patients during preoperative preparation, ceruloplasmin is administered at a dose of 1, 5 - 2, 0 mg / kg; the course of treatment is 7 to 10 infusions (daily or every other day, depending on the condition of the patient).
In the postoperative period, a single dose is determined by the amount of blood loss and ranges from 1.5 mg / kg (with low blood loss) to 6 mg / kg (with large blood loss); the course of treatment consists of daily (1 time per day) infusions for 7 to 10 days.
When conducting chemoradiotherapy, a single dose is 4-6 mg / kg, the course of treatment consists of 10-14 injections (3 injections per week). For patients with hemoblastosis, a single dose is 1, 5 - 3, 0 mg / kg, the course of treatment is 7 - 10 injections, prescribed daily 1 time per day.
In acute osteomyelitis, a single dose is 2.5 mg / kg, the course of treatment consists of 5 injections, prescribed daily or every other day. In chronic osteomyelitis, ceruloplasmin is administered at 5 mg / kg 2 to 3 times with an interval of 1 to 2 days and then 3 to 7 injections at 2.5 mg / kg every other day.
At the beginning of treatment with ceruloplasmin, a sensation of a rush of blood to the face, nausea, chills, a short-term increase in body temperature may appear; skin rashes (urticaria). In these cases, reduce the dose, reduce the rate of administration or cancel the drug.